Pfizer Launches Biosimilar Trastuzumab In US
Rival To Herceptin Competes In An Increasingly Crowded Market
Executive Summary
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.
You may also be interested in...
Pfizer Asks For Biden’s Co-operation To Incentivize Biosimilar Uptake
Pfizer is looking for the Biden administration’s co-operation to address the policy issue of affordability and access to biosimilars. In the first quarter, the company’s biosimilars segment grew by 84% on the back of new launches, especially in the US where biosimilars sales nearly doubled.
Pfizer’s Upjohn Business Sees ‘Expected Drop’ Of 37%
Despite reporting a 37% drop in Upjohn’s first-quarter sales, Pfizer has insisted that the decline was consistent with its expectations for the business. Meanwhile, biosimilars sales have been boosted by US launches as sterile injectables and hospital medicines have seen a lift from COVID-19.
Teva Sticks With 10% Discount For Trastuzumab
Teva and Celltrion have launched their Herzuma trastuzumab biosimilar in the US at a 10% discount to the Herceptin brand. The discount matches that offered for their Truxima rituximab biosimilar and compares to steeper discounts offered by competing biosimilars.